Comoros vs Luxembourg: Share of the population living with HIV receiving antiretroviral therapy
Comoros
84.1%
in 2024
Luxembourg
83.8%
in 2024
Comoros rank
42nd
Luxembourg rank
43rd
Share of the population living with HIV receiving antiretroviral therapy over time
- Comoros
- Luxembourg
How they compare
Comoros currently reports 84.1% against 83.8% in Luxembourg, a difference of 0.3%.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Luxembourg ahead.
Comoros ranks 42nd and Luxembourg ranks 43rd of 149 countries.
Luxembourg has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Comoros | Luxembourg | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 14.0% | 14.0% | Luxembourg |
| 2000s | 0.0% | 44.5% | 44.5% | Luxembourg |
| 2010s | 30.2% | 63.8% | 33.5% | Luxembourg |
| 2020s | 65.8% | 79.0% | 13.2% | Luxembourg |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Comoros or Luxembourg?
- Comoros, at 84.1% against 83.8% in Luxembourg as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Comoros and Luxembourg?
- 0.3%, with Comoros ahead.
- How many years of comparable data are there for Comoros and Luxembourg?
- 35 years are reported by both, from 1990 to 2024.
- How do Comoros and Luxembourg rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Comoros ranks 42nd and Luxembourg ranks 43rd of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.